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Abstract 
The hsa-mir-483 locus is located at chromosome 11p15.5 within intron 2 of the IGF2 locus. 
Because of its location, de-regulated in Wilms’ tumor and other neoplasia, I hypothesized 
that this microRNA had a potential role in  tumors. By analyzing 19 Wilms’ tumors, I proved 
that miR-483-3p is indeed over-expressed in 100% of the cases and a co-regulation with the 
over-expression of IGF2 was found.   
However, several other types of common adult cancers exhibit high or even extremely high 
levels of miR-483-3p expression without IGF2 over-expression. Indeed, independently from 
IGF2, the expression of the miR-483-3p could also be induced by the oncoprotein -catenin 
through a novel interaction with the basic Helix-Loop-Helix protein upstream stimulatory 
transcription factor 1 (USF1). 
 I also show that -catenin itself is a target of miR-483-3p, triggering a negative regulative 
loop that becomes ineffective in cells harbouring activating mutations of -catenin pathway. 
The potential oncogenic role of miR-483-3p was supported by the findings that its ectopic 
expression protects cells from apoptosis and, conversely, its inhibition increase the level of 
apoptosis. To understand the mechanisms of its action, I investigated potential gene targets. 
Among these, an important pro-apoptotic protein, Puma, were inhibited by miR-483-3p. My 
results indicate that miR-483-3p functions as an anti-apoptotic oncogene, coordinately over-
expressed with IGF2 in Wilms’ tumors or induced by -catenin activation in other tumor 
types. 
 
Significance 
IGF2 is a fetal growth factor where abnormally high expression has been associated with the 
Beckhwith-Wiedeman syndrome that predisposes to the development of nephroblastoma, 
hepatoblastoma and rhabdomyosarcoma. Here I show that miR-483-3p, located within intron 
2 of IGF2 gene, is overexpressed in all the Wilms’ tumors I studied. I also show this 
microRNA target a  proapoptotic protein, Puma, and behave as an antiapoptotic oncogene. 
Moreover I demonstrate that dysregulation of miR-483-3p can also occur independently of 
IGF2 dysregulation. In this case miR-483-3p is regulated by -catenin oncogene and may 
contribute to its antiapoptotic activity. 
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Introduction 
Genetic and epigenetic abnormalities at chromosomal region 11p15.5 have been associated 
with various human neoplasms and with the cancer-predisposing Beckwith-Wiedeman 
syndrome (BWS). In particular, loss of alleles and gene duplication at 11p15 are typically 
detected in more than 80% of Wilms’ tumors 1-5 and, albeit less frequently, in more common 
adult neoplasms 
6-9
.  
Two close imprinted loci, that harbor at least eight mono-allelically expressed genes, are 
present at chromosome region 11p15.5. The aberrant regulation of genomic imprinting at 
11p15.5 was involved in human cancer 
10-12
. Aberrant methylation at the H19 maternal locus 
leads to the reactivation of the silent IGF2 allele 
10,13-16
 and the loss of maternal allele 
methylation at the KvDMR1 locus was linked to reduced expression of the cyclin-dependent 
kinase inhibitor CDKN1C/p57 gene and other imprinted genes 
11,12,17-19
. These studies point 
to the existence of oncogenic, IGF2, as well as tumor suppressive, CDKN1C/p57, functions 
within the 11p15.5 chromosomal imprinted region.  
IGF2 is a fetal growth factor, whose abnormal expression has been involved in the Beckwith-
Wiedemann syndrome, which predisposes to the development of nephroblastoma, 
hepatoblastoma, and rhabdomyosarcoma. Biallelic expression of IGF2 gene, consequent the 
loss-of-imprinting (LOI) at the IGF2 locus, occur in 40-50% of Wilms’ tumor 5,20 and it is 
thought to be an early event in carcinogenesis. So it has been suggested that increased IGF2 
could lead to an enhanced cellular proliferation, differentiation failure and tumor 
development. However, a transgenic mouse model for IGF2 over-expression exhibited many 
of the features associated with the Beckwith-Wiedemann syndrome, including prenatal 
overgrowth, polyhydramnios, fetal and neonatal lethality, disproportionate organ overgrowth 
including tongue enlargement, and skeletal abnormalities, but did not develop tumors 
21
. 
These results suggest that additional cofactors cooperate with IGF2 in promoting human 
cancer. Recently, the IGF2 locus was shown to harbor a miRNA, the mir-483 locus, within 
its second intron 
22
.   
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Fig.1 Genomic structure of the 11p15.5 chromosome region and its imprinted genes.(A) Location of the 
genes mapping in the 11p15.5 chromosome region and their imprinted status. Red arrows, on the top of the 
panel, indicate the maternal allele expression, blue arrows the paternal allele expression whereas black arrows 
indicate the biallelic expression.  (B) Simplified model of the imprinted status of the 
CDKN1C/KCNQ10T/KvLQT1 and IGF2/H19 genes imprinted locus   (from J Clin Invest. 2000;105(3):247–
252). (C) Schematic representation of the tridimensional structure obtained by the interaction between CTCF-
Cohesin, other proteins to permit the monoallelic expression of the IGF2 and H19 genes. DNA elements are 
indicated as follows: CTCF AD (red bar); ICR (purple bar), and CTCF DS (Cerise bar), Enhancer is yellow 
oval. Pink and pale blue ovals represent the CTCF/cohesin complexes. CpG methylation is depicted as filled 
lollipops. On the paternal allele, co localisation of CTCF and cohesin at CTCF AD, and CTCF DS brings these 
regions together. The methylated ICR does not bind CTCF and is thus excluded from CTCF/cohesin interacting 
regions. The exclusion of the ICR may enable the IGF2 gene promoters and H19 enhancer region to interact, 
(shown by yellow oval close to IGF2 arrow) even though they are on different looping domains. (The H19 
domain is shaded.) On the maternal allele, CTCF/cohesin can bind to the unmethylated ICR which can then 
interact with other CTCF/cohesin sites. 
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Fig.2 Wnt/β-catenin signaling (from Cell signaling technology, http://www.cellsignal.com). The figure show 
how β-catenin (blue oval) could be part of the membrane E-Cadherin/α-catenin complex,  compounded  to the 
APC/Axin/GSK3β/WTX complex for its degradation or be in the nucleus to act as a transcription factor. Every 
step of this pathway could be regulated by numerous protein/enzyme where the most important is by the Wnt-
Frizzled molecules able to block the β-catenin degradation by the APC/Axin/GSK3β complex. 
 
β-catenin is a multifunctional protein involved in cell-cell adhesion when it is localized to the 
cellular membrane 
23
, and in transcriptional regulation by translocation into the nucleus 
through the Wnt pathway 
24
. Wnt signaling is an important molecular pathway required for 
cellular differentiation, tissue homeostasis, and tissue morphogenesis.  Wnt/β-catenin 
signaling is one of the most commonly activated pathways in cancer and several Wnt 
signaling related gene mutations have been  described: adenomatous polyposis coli (APC) 
WTX 
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and protein phosphatase 2 regulatory subunit A (PPP2R1B) mutations in colorectal cancer 
25
, 
axin1 mutation in hepatocarcinoma 
26,  WTX gene mutations in Wilms’ tumor 27 and β-
catenin gene (CTNNB1) itself was shown to be mutated 
28-30
 in the amino terminal region 
employed for degradation by the GSK3β -APC-Axin-WTX complex 27,31. These mutations 
prevent β-catenin degradation and result in its accumulation in the nucleus where it acts as a 
specific transcriptional co-activator of the DNA binding T cell factor/lymphoid enhancer 
factor protein family (TCF/LEF). Among the targets of this family are important genes 
involved in tumorigenesis such as MYC, CCND1, CJUN and FRA1. 
32,33
 (Fig.2). 
 
Fig.3 Biogenesis of miRNAs and assembly into protein complexes. miRNA precursor molecules (pri-
miRNAs) fold into hairpin structures that contain imperfect base-paired stems in a two-step process catalyzed by 
two different RNase III-type endonucleases. Drosha first cleaves pri-miRNAs,forming _70 nucleotide hairpins 
(pre-miRNAs) in the nucleus. Subsequently, pre-miRNAs are transported to the cytoplasm by Exportin 5, where 
they are cleaved by Dicer to yield _20-bp miRNA duplexes. After processing, miRNAs are assembled into RNP 
(ribonucleic protein) complexes, called miRNPs, with proteins of the AGO family. miRNPs tether to the 3_UTR 
of a mRNA target to repress protein synthesis. In the case of perfect bp alignment, the miRNP complex cleaves 
the duplex miRNAmRNA; however, multiple mechanisms 34 are used on duplex miRNA:mRNA with imperfect 
complementary.  
MicroRNAs (miRNAs) are small non-coding RNAs that modulate gene expression by base 
pairing to the target messenger RNAs (mRNAs) and
 
by inhibiting their translation and/or 
promoting their degradation 
35
 (Fig.3). MicroRNAs play a critical role in the normal 
maintenance of fundamental cellular processes and their deregulation in human neoplasm has 
been proven to affect a large number of molecular pathways related to cancer 
36-38
. Indeed 
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microRNA aberrant expression of miRNAs has been detected in any human neoplasm and 
miRNAs were found to play a central role in all molecular pathways affecting cancer traits 
36,38,39
.  Since the miR-483 locus is dysregulated in tumors involving the β-catenin pathway 40-
42
 I investigated also their possible connection. Here I demonstrate that expression of miR-
483 can be induced independently of its host gene IGF2 by the oncoprotein -catenin through 
a novel interaction with the basic Helix-Loop-Helix protein upstream stimulatory 
transcription factor 1 (USF1) . I also show that -catenin itself is a target of miR-483-3p, 
triggering a negative regulative loop that becomes ineffective in cells harbouring activating 
mutations of -catenin pathway. 
Therefore, I illustrate the potential oncogenic activity of miR-483-3p, one of the mature 
products of the hsa-mir-483 locus, which is located within the IGF2 locus at chromosome 
11p15.5. My results provide evidences for a role of this miRNA as an anti-apoptotic 
oncogene, which may cooperate with IGF2 in  tumorigenesis. 
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Materials and Methods 
Primary tumors. Primary tumor RNAs were obtained from 19 Wilms’ tumor, 3 adjacent 
patient normal tissues, 2 adult kidneys; 27 hepatocarcinoma (HCC), 7 cirrhotic and 2 normal 
liver tissues; 23 colorectal cancers (CRC) and 5 normal colon mucosa; 19 breast cancers 
(BrCa) and 4 normal breast tissues. All tissue samples were collected at surgery, immediately 
snap frozen in liquid nitrogen, and stored at -80°C until RNA extraction. Total RNA was 
isolated using Trizol (Invitrogen) according to manufacturer’s instructions.  
Cell lines and transfection. HEK293 (ATCC number CRL-1573), HepG2 (ATCC number 
HB-8065), HCT116 (ATCC n. CCL-247) cell lines were cultured with Iscove’s modified 
Dulbecco’s medium with 10% fetal bovine serum. hsa-miR-483-3p precursor (Sanger 
accession MI0002467) and Negative control 2 ribo-oligonucleotide were from Applied 
Biosystems/Ambion. Anti-microRNA oligonucleotides (AMOs) against miR-483-3p and 
against the GFP gene (AMO Negative Control) were from Fidelity Systems (Gaithersburg 
MD, USA). RNA interfering for BBC3/PUMA and scramble control were from Santa Cruz 
(Santa Cruz, CA). . siRNA for MYC (cat. L-003282-00-0005), CTNNB1 (cat. L-003482-00) 
and scramble negative control (cat. D-001810-10-20) were from Dharmacon. Transfection of 
miRNAs, AMOs and expression vectors was carried out with lipofectamine 2000 (Invitrogen, 
cat. 116688-019) in accordance with manufacturer’s procedure. 
Luciferase assays and vectors. The human 3’UTRs of BBC3/PUMA and CTNNB1 were 
amplified by PCR using the primers indicated in Table 1 and cloned downstream of the 
firefly luciferase gene in the pGL3-Control vector (Promega). Substitutions into the miR-483-
3p binding sites of the 3’UTR genes were introduced by using Quick-Change Site direct 
Mutagenesis Kit (Stratagene, CA, USA) following the manufacturer’s instructions using the 
primers indicated in Table 1. As a reference, the pRLTK vector (Promega), which expresses 
the renilla luciferase, was used. Transfection was conducted in HEK293, HCT116 and 
HepG2 cells cultured in 24-well plates, each well was cotransfected with 400 ng of pGL3-
control vectors together with 40 ng of pRLTK reference vector (Promega) and 30 pmol of 
miR-483-3p or Negative control 2 or AMOs or methylated control oligonucleotide. Twenty-
four hours after transfection, firefly and renilla luciferase activities were measured using the 
Dual-Luciferase Report Assay (Promega). β-catenin and USF1 expression vectors were 
generated cloning β-catenin cDNA and USF1 cDNA into the pIRES-Neo2 (Clontech), and 
pCMV-Tag (Agilent Technologies) vectors see Table 2 for primers sequences. To test the β-
catenin nuclear activity, the pGL3-OT and pGL3-OF luciferase responsive vectors were used 
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43
. pGL3-OT is a TCF-LEF responsive reporter, pGL3-OF is a negative control with a 
mutated TCF-LEF binding site. Each transfection was repeated at least twice in triplicate.  To 
analyze the promoter of the miR-483 I used the pGL4 luc2 .1 (Promega) where I cloned the 
SV40 enhancer downstream the luciferase gene. 
Western blots analysis. HEK293, HepG2 and SW480 cell lines were transfected with 30 
pmol of miR-483-3p, AMOs and controls sequences in 24-well plates. After 48 hours cells 
were collected, lysed in Laemmli 2X buffer and analyzed by western blot to assess the 
expression of PUMA using monoclonal antibodies (Cell Signaling, anti-PUMA antibody 
#4976). Primary antibody was incubated 2 hours at room temperature and then peroxidase 
conjugated anti-mouse or anti-rabbit antibodies were incubated 30 minutes at room 
temperature. Detection was conducted by chemiluminescent enhanced assay (WesternBreeze 
Chemiluminiscent Kit cat. WB7104, Invitrogen). β-actin antibody (Cell Signaling, β-Actin 
Antibody #4967) or Ponceau staining were used to normalize protein loading. To quantify 
western blot signals, digital images of autoradiographies were acquired with Fluor-S 
MultiImager, and band signals were quantified in the linear range of the scanner using 
specific densitometric software (Quantity One). 
RNA isolation and Quantitative Real time RT-PCR (qRT-PCR). Purification of total 
RNA using TRIzol reagent (Invitrogen, Carlsband, CA, USA) was carried out following the 
manufacturer’s instructions. Mature microRNA expression was assayed by Taqman 
MicroRNA assay (Applied Biosystem) specific for miR-483-3p (P/N: 4378094) and 
normalized on RNU6B (P/N: 4373381). Five ng of total RNA was reverse transcribed using 
the specific looped primer and real time quantitative PCR was conducted using the standard 
Taqman MicroRNA assay protocol on a Biorad-Chromo4 thermal cycler. The 20 μL PCR 
included 1.33 μL reverse transcription product, 1X Taqman Universal PCR Master Mix, No 
AmpErase UNG (P/N 4324018 (Applied Biosystem), 0.2 μmol/L Taqman probe, 1.5 μmol/L 
forward primer, 0.7 μmol/L reverse primer. The reaction was carried out in a 96-well PCR 
plate at 95°C for 10 min followed by 40 cycle of 95° C for 15 sec and 60°C for 1 min. Each 
sample was analyzed in triplicate. qRT-PCR for mRNAs was performed using 500 ng of total 
RNA for each sample according to the manufacturers’ instruction (High capacity cDNA 
Reverse Transcription Kit, Applied Biosystems) and the real time reaction using SYBR green 
technologies (Power SYBR green PCR Master Mix, Applied Biosystems) on the Biorad-
Chromo4 instrument. The 20 μL PCR included 1 μL reverse transcription product, 1X Power 
SYBR green PCR Master Mix, (P/N 4368577, Applied Biosystem),  0.4 μmol/L forward 
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primer, 0.4 μmol/L reverse primer. The reactions were incubated in a 96-well PCR plate at 
95° C for 10 min followed by 40 cycle of 95° C for 15 sec and 60° C for 1 min. Each sample 
was analyzed in triplicate. TaqMan gene expression assays was performed for IGF2, 
BBC3/PUMA and CDKN1A/P21, primiR-483 genes using primers and probes 
(Hs01005963_m1, Hs00248075_m1, Hs99999142_m1) obtained from Applied Biosystems 
(Applied Biosystems, Foster City, CA). The expression of 18S RNA was used as endogenous 
reference control. ). To avoid genomic contamination in the quantification of the IGF2 intron 
2 and primiRNA-483 RNA samples were previously treated with DNAse (TURBO DNA-
free™ Kit, cat. AM1907, Ambion). The list of primers that I used herein is shown in Table 2. 
The level of miRNA and mRNA were measured using Ct (threshold cycle). The amount of 
target, normalized to an endogenous reference and relative to a calibrator, is given by: 2
-∆∆Ct 
(Comparative Ct method, Applied Biosystem User Bulletin #2).  
Northern blot analysis. RNA samples (10 µg each) were electrophoresed on 15% 
acrylamide and 7 mol/L urea Criterion precasted gels (Bio-Rad) and transferred onto Hybond 
N+ membrane (Amersham Biosciences). Membranes were hybridized as previously describes 
44
 with oligonucleotide probes corresponding to the complementary sequences of the mature 
miRNAs: miR-483-3p 5’-UCACUCCUCUCCUCCCGUCUU-3’ and the reference U6 RNA 
5’-GCAGGGGCCATGCTAATCTTCTCTGTATCG-3’. 
Cell death and cell viability assays. MTT assay was carried out on HEK293 cell line. 
HEK293 was cultured in 24-well plates the day before miR-483-3p or AMOs transfection. 
After 24 hours from transfection, cells were treated with doxorubicin (0.4 μg/ml) for 
additional 24 hours. The assay was performed in accordance with manufacturer’s protocol 
(Sigma, TOX-1). Each experiment was performed in triplicate. Nuclear fluorescein staining 
based on labeling of DNA strand breaks by Terminal deoxynucleotidyl transferase (TUNEL-
reaction) was performed on HepG2 cell line according to the manufacturer’s instructions (In 
situ cell death detection kit, Cat. No.11684795910, Roche). The experiment was performed in 
triplicate and analyzed on microscope Zeiss Axiovert 200 at 100X magnification, images was 
acquire with the CCD Cascade Photometrics 512b. Quantification of positive nuclei was 
calculated by counting fluorescent spots in 10 images (10X10 magnifications) for each 
experiment. Caspase 3/7 activity assay was performed on HCT116 cell line. HCT116 was 
cultured in 96-well plates the day before miR-483-3p, AMOs and controls transfection. After 
24 hours from transfection, cells were treated with Nutlin-3 (5 μM) or 5-Fluoruracil (from 0 
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to 50 μM) for additional 6/24 hours then the assay was performed in accordance with 
manufacturer’s protocol (Promega, Caspase-Glo 3/7 assay, G8090).  
Generation of stable cell lines over-expressing miR-483-3p and antimiR-483-3p. 
HCT116 cells were infected with the PMIRH483 expression plasmid containing the full-
length miR-483-3p and the GFP gene under the control of two different promoters 
(PMIRH483PA-1, System Biosciences, Mountain View, CA). HCT116 and HepG2 cells 
were infected with the pSIH vector (System Biosciences, Mountain View, CA) containing the 
antisense sequence for miR-483-3p (Table 1) using the Lentivector-based Anti-MicroRNAs 
technology (miRZIP
TM
, System Biosciences, Mountain View, CA). An empty vector was 
used as control.  Pre-miR-483-3p, antimiR-483-3p expression and control constructs were 
packaged with pPACKH1 Lentivector Packaging Plasmid mix (System Biosciences) in 293-
TN packaging cell line. Viruses were concentrated using PEG-it™ Virus Precipitation 
Solution and titers analyzed using UltraRapid Lentiviral Titer Kit (System Biosciences). 
Infected cells were selected by FACS analysis (FACS Calibur, Becton Dickinson 
Immunocytometry Systems). Infection efficiency >90% was verified by fluorescent 
microscopy. 
In vivo studies. Animal studies were approved by institutional ethical committee. HepG2 
cells were transfected in vitro with 2’-O-methyl RNA oligonucleotide complemenmtary to 
miR-483-3p (anti-miR oligonucleotide: AMO-483-3p), AMO-Negative control from Fidelity 
Systems (Gaithersburg MD, USA) and siRNA against IGF2 gene from Thermo-Scientific 
Dharmacon (Lafayette, CO, USA). At 24 h after the transfection, 10
7
 viable cells per mouse 
were injected intraperitoneally into ten Nod-Scid mice (Charles River Breeding 
Laboratories). After 35 days, the mice were sacrificed, necropsies were performed, and all 
tumors per mouse were weighed. For athymic “nude” mice experiments, HepG2 cells (10 × 
10
6
 cells/200 ul) were injected subcutaneously into the flanks of nude mice 24 h after 
transfection with AMO-483-3p (4 injection), AMO Negative Control (4 injection) or siRNA 
IGF2 (6 injection). Tumors were counted after 20 days. 
Protein isolation, immunoblot analisis and immunoprecipitation. Cells were collected 
from 6-well plates using trypsin-ethylenediaminetetraacetic acid (EDTA) (Sigma) and 
dissolved in lysis buffer (M-PER Mammalina Protein Extraction reagent, cat. 78501, Thermo 
Scientific) freshly supplemented with a complete protease inhibitor and phosphatase inhibitor 
cocktails 1 and 2 (Roche, Indianapolis, IN, USA) in accordance with manufacturer’s 
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procedure. Nuclear extracts were prepared dissolving cells in nuclear and cytoplasmic 
extraction reagents (cat. 7833, Thermo Scientific) and following the manufacturer’s 
procedure. After electrophoresis and blotting primary antibodies (Cell Signaling, anti-
CTNNB1 #9562, anti-MYC #5605; Santa Cruz, anti-USF1 sc-229) were incubated over night 
at +4°C temperature and then peroxidase conjugated anti-mouse or anti-rabbit antibodies 
were incubated 1 hour at room temperature. Detection was conducted by chemiluminescent 
(Pierce ECL Western Blotting Substrate cat. 32106, Thermo Scientific). β-actin antibody 
(Cell Signaling, β-Actin Antibody #4967) or Vinculin antibody (Millipore, cat. MAB3574) 
were used to normalize protein loading. To quantify western blot signals, digital images of 
autoradiographies were acquired with Fluor-S MultiImager, and band signals were quantified 
in the linear range of the scanner using specific densitometric software (Quantity One). 
Immunoprecipitation was carried out with 100 µg of nuclear extracts in 500µl of binding 
buffer (10mM Tris, 50mM KCl, 1mM DTT; pH 7.5) with 2 µg of USF1 (Santa Cruz, sc-229) 
or CTNNB1 antibody (Cell Signaling, #9562) 2 hours at +4°C with gentle rotation. The 
immunoprecipitated was recovered by 25 µl of Protein A/G PLUS-Agarose (Santa Cruz, sc-
2003) over night at +4°C with gentle rotation. Then the immunoprecipitated was washed in 
0.1% NP40 three times and analyzed by western blot. 
Electrophoretic mobility shift assay (EMSA). Protein/DNA binding was determined by 
electrophoretic mobility shift assay (EMSA) according to the manufacturer’s procedure with 
biotinylated probes (Pierce, LightShift Chemiluminescent EMSA kit cat. 20148), see Table 1 
for oligo sequences. Samples were incubated with Ebox wt probe or the mutant form and 
with 100X Ebox wt unlabeled probe, and with specific polyclonal USF1 antibody (C-20, sc-
229, Santa Cruz), before the addition of the probe. The DNA-protein complexes were 
resolved on 5% (w/v) nondenaturing acrylamide gels and visualized by exposure to 
autoradiographic films. 
Pull down experiment. Pull-down assay was performed by using 10nmol of recombinant 
proteins GST (# ab85244, Abcam), GST-bcatenin (#ab63175, Abcam) and His-USF1 
(#ab82069 Abcam). Reactions were carried out in binding buffer (150mM NaCl, 20mM Tris-
HCl pH8, 1% NP40, 1mM EDTA), 1 mM PMSF and protease inhibitors at 4°C for 1 h of 
gentle rocking. The protein-protein complexes formed on the resin (Glutathione Sepharose 4 
Fast Flow, Amersham or Ni-NTA Agarose, Qiagen) were brought down by centrifugation. 
The resin was washed five times for 5’ at 4°C with 1 ml of cold wash buffer (250mM NaCl, 
20mM Tris-HCl pH8, 1% NP40, 1mM EDTA). The protein complexes were resolved on 
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SDS-PAGE, immunoblotted and detection was conducted by chemiluminescent metti l’ECL 
(Pierce ECL Western Blotting Substrate cat. 32106, Thermo Scientific). 
DNA purification and Methylation analysis. Genomic DNA was isolated from cell lines 
and tissue by standard treatment with sodium dodecyl sulfate and EDTA in the presence of 
200 μg/ml of proteinase K, followed by phenol / chloroform extraction and ethanol 
precipitation. The methylation status of miR promoters was determined by Bisulfite 
Sequencing PCR (BSP) 
45
. One microgram of genomic DNA was subjected to treatment with 
the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's instructions. Specific 
primers for PCR and sequencing were designed through the Methyl Primer Express v1.0 
software (Applied Biosystems) (Table 1). 
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Table 1. Oligonucleotide sequences used for cloning, qRT-PCR, mutational analysis, site direct mutagenesis, bisulfate 
sequencing and EMSA assay. 
 Gene  Name  Sequence  
Gene 
Cloning  
CTNNB1 CTNNB1_215F ATGGCTACTCAAGCTGATTTGATGG 
 CTNNB1 CTNNB1_2560R ACAGGTCAGTATCAAACCAGGC 
 CTNNB1_3’UTR bCAT_2677F_Xba GttctagaTGCCACAAAAACAGGTAT 
 CTNNB1_3’UTR bCAT_3193R_Xba GttctagaTTCAAAGCAAGCAAAGTC 
 USF1 USF1_BamHI_F caaggatccCCCCCTCACAGAGAGATGAA 
 USF1 USF1_EcoRI_R caagaattcGGATTAGGCTGTTGCTCCTG 
 
BBC3/PUMA PUMA_3’UTR_F GTGGACGTCAGGGACTCG 
 
BBC3/PUMA 
miR-483 
miR-483 
 
PUMA_3’UTR_R 
MIRZIP_AS_miR-
483-3p_U 
MIRZIP_AS_miR-
483-3p_L 
TTGAAAAGGAAACATACAAAAATCA 
CCGAGCTCGGGATCCTCACTCCTCTCCTCCCGTCTTCTTCCTGTCAGAAAGACGGGAGGAGAGGAGTGATTTTTGAATTCGCGGCCGC 
GGCGGCCGCGAATTCAAAAATCACTCCTCTCCTCCCGTCTTTCTGACAGGAAGAAGACGGGAGGAGAGGAGTGAGGATCCCGAGCTC 
qRT-PCRs   
(SYBR 
green) 
IGF2 IGF2_3044F TCCTCCCTGGACAATCAGAC 
 IGF2 IGF2_5965R AGAAGCACCAGCATCGACTT 
 IGF2 IGF2_5965F AAGTCGATGCTGGTGCTTCT 
 IGF2 IGF2_7866R CGGAAACAGCACTCCTCAA 
 IGF2 IGF2_6907F GTGAAATGGGCTCACAGGAT 
 IGF2 IGF2_7252R AGCAATGCTCAGCTGGAAG 
 IGF2 IGF2_7846F CGTTGAGGAGTGCTGTTTCC 
 IGF2 IGF2_8307R GGACTGCTTCCAGGTGTCAT 
 IGF2_3’UTR IGF2-3 CTTGGACTTTGAGTCAAATTGG 
 IGF2_3’UTR IGF2-2 CGGGGATGCATAAAGTATGAG 
 18S 18s_F  CTGCCCTATCAACTTTCGATGGTAG 
 18S 18s_R  CCGTTTCTCAGGCTCCCTCTC 
qRT-PCRs 
( Applied 
Taqman 
probe)  
IGF2-INS Hs01005963_m1  
 
CTNNB1  Hs00355045_m1   
 
MYC Hs00153408_m1 
 
 b-actin Hs00357333_g1  
 Pri-MiRNA hsa-mir-483 Hs03293803_pri  
 hsa-miR-483-5p Assay ID 002338   
 hsa-miR-483-3p Assay ID 002339  
 RNU6B Assay ID 001093  
Mutational 
analysis  
CTNNB1 BCAT3 AAAATCCAGCGTGGACAATGG 
 CTNNB1 BCAT2 TGTTCTTGAGTGAAGGACTGA 
 APC APC_3361F TTTTGGACAGCAGGAATGTG 
 APC APC_4091R TGCTGGATTTGGTTCTAGGG 
 APC APC_4072F CCCTAGAACCAAATCCAGCA 
 APC APC_4840R TGTTGGCATGGCAGAAATAA 
 Axin1 Axin1_745F CAGGCCACTATGGAGGAAAA 
 Axin1 Axin1_1583R CTCTCAGGGTTCTCCTCGTG 
 Axin1 Axin1_1429F ATGGAGGAGGAAGGTGAGGA 
 Axin1 Axin1_2186R AGGGACAAGGGTCTGGAGTT 
Site direct 
mutagenesis    
miR-483 
(promoter)_Ebox site 
483_Ebox-mut_F CACCTGACACTCTTAGGTCTGGATCTTTACCACC 
 
miR-483 
(promoter)_Ebox site 
483_Ebox-mut_R GGTGGTAAAGATCCAGACCTAAGAGTGTCAGGTG 
 CTNNB1 CTNNB1_483mut_F AACAATACAAATGGATTTTGTCGCCTCCTCAAGAAGTGAAGAATG 
 CTNNB1 CTNNB1_483mut_R CATTCTTCACTTCTTGAGGAGGCGACAAAATCCATTTGTATTGTT 
 
miR-483 
(promoter)_CTCF_BS1 
CTCF_mut1F CTCCTGCTcactggCTGATaGCAtCTGCCCTTTGGC 
 
miR-483 
(promoter)_CTCF_BS1 
CTCF_mut1R cAGaTGCtATCAGccagtgAGCAGGAGCCCCATCAC 
 
miR-483 
(promoter)_CTCF_BS2 
CTCF_mut2F CCTTTGGCAAGGTGGAGCCCCCAGCGACCTTCCC 
 
miR-483 
(promoter)_CTCF_BS2 
CTCF_mut2R CCACCTTGCCAAAGGGCAGGTGCCATCAGCCGGA 
 
BBC3/PUMA BBC3_mutF AGGAGTCTGAATTAGGGGAGGGATGGCCCAG 
 
BBC3/PUMA BBC3_mutR CTCCCCTAATTCAGACTCCTCCCTCTTCCGAG   
Bisulfite 
Sequencing 
PCR  
miR-483 (promoter) 483MetF2 GGTAGGAAGTGGTATTGTAGGG  
 miR-483 (promoter) 483MetR2 ACCCCCACAAAAAAAACTACT  
EMSA 
probes 
miR-483 (promoter) 483_Ebox wt ACCTGACACTCACCACGTGACATCTTTACCACC  
 miR-483 (promoter) 483_Ebox mut ACCTGACACTCTTAGGTCTGGATCTTTACCACC  
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Results 
miR-483-3p is over-expressed in Wilms’ tumor and common adult human cancers in 
concert with IGF2. Because of its location within the IGF2 locus, I evaluated miR-483-3p 
expression in Wilms’ tumor. Biopsies from 19 Wilms’ tumors, four normal kidney tissues 
(three of which matched with Wilms’ tumor samples), one fetal kidney and one fetal liver as 
positive control were analyzed. Up-regulation (from 4 to 40-fold) of miRNA expression was 
found in 73% of Wilms’ tumors when compared with fetal kidney and in 100% of the cases 
when compared to non-tumoral kidney tissues (Fig. 3A-B).  Northern blot analysis confirmed 
the qRT-PCR data (Fig. 3C).  
Since mir-483-3p is located within the IGF2 gene, I compared their levels of expression: a 
positive correlation between IGF2 messenger RNA and miR-483-3p expression was found. 
By using two sets of primers spanning the junctions between exons 1-2 or 2-3 of the IGF2 
cDNA sequence I found strong positive coefficients of correlation with miR-483-3p in both 
cases (R=0.94, p<0.0001 for product E, and R=0.60, p=0.004 for product F) (Fig. 3D).  These 
results indicate that the joint over-expression of at least two functional elements from the 
IGF2 locus, the IGF2 protein and miR-483-3p, may act in Wilms’ tumors to promote 
tumorigenesis.  
I investigated the potential involvement of miR-483-3p in common human neoplasms. I 
analyzed the expression of miR-483-3p in breast, colon and liver human cancers and I found 
that over-expression of miR-483-3p was indeed present, suggesting a wider involvement of 
this miRNA in human tumorigenesis. In primary colon, breast and liver carcinomas (Fig. 4A-
C), I compared the expression of miR-483-3p of tumors with the average expression of non-
tumor histological normal tissues. Considering the variability of miR-483-3p expression in 
non-tumor counterparts, only tumors exhibiting a fold-change > 10 in comparison with the 
average expression of non-tumor normal tissues were scored as over-expressed: 33% of 
HCCs, 31% of breast and 27% of colorectal cancers exhibited significant up-regulation. 
Interestingly, cirrhotic liver tissues, a condition that predisposes to HCC, already exhibited an 
increased miR-483-3p expression (from 3 to 14-fold) when compared to normal liver tissues 
(p-value < 0.05) (Fig. 4A).   
I observed that, as in Wilms’ tumors, the up-regulation of miR-483-3p was linked with IGF2 
expression: a positive Spearman coefficient of correlation of 0.69 for HCCs (p-value 
<0.0001) and 0.86 for CRCs (p-value <0.0001) (Fig. 4A-B). 
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Figure 3. miR-483-3p and IGF2 expression in Wilms’ tumor. (A) miR-483-3p relative expression analysis by 
quantitative real time PCR on 19 samples of primary Wilms’ tumor, 3 adjacent non tumoral tissues, fetal kidney, 
cell line HEK293 and fetal liver tissue. Each sample data was normalized to the endogenous reference RNU6B 
and related to the Fetal Kidney (calibrator) miR-483-3p expression (2
-∆∆Ct
 method). (B) Different expression 
from normal to tumoral tissue was pointed out in samples WT_38, _39 and _40. (C) Northern blot analysis of 
miR-483-3p and RNU6B in 6 Wilms’ tumor samples, 2 normal adult kidney, 1 normal adult liver and HepG2 
cell line. (D) Genomic structure of IGF2 gene (black arrow); coding sequence is depicted as light gray arrows, 
miR-483 is indicated in the second IGF2 intron. Black bars e and f show the cDNA amplified regions used to 
analyze IGF2 expression that was compared to the miR-483-3p expression in panels immediately below. IGF2 
expression data were normalized on RNA 18S and related to IGF2 fetal kidney expression (2
-∆∆Ct
). Correlation 
coefficient (R)
 
and the p-value (p) are shown.  
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In spite of these significant positive correlations, some tumor samples (HCC_02, HCC_04, 
HCC_10, HCC_13, HCC_16, HCC_21, HCC_26, HCC_29, CRC_188, CRC_130, 
CRC_148) exhibited a divergent expression of IGF2 and miR-483-3p, suggesting the 
existence of multiple mechanisms of miR-483-3p regulation. 
 
 
Figure 4. miR-483-3p and IGF2 expression in adult human cancers. miR-483-3p relative expression by 
quantitative real time RT-PCR. The expression of miR-483-3p was normalized to the endogenous gene RNU6B 
(black bars) while the expression of IGF2 was normalized in 18S RNA (gray bars). Expression data were related 
to the average expression of normal samples of each tissue (2
-∆∆Ct
 method). Expression of the locus IGF2/miR-
483-3p was investigated in (A) 27 HCCs and 7 non tumoral cirrhotic livers (CE), which were related to 2 
normal liver tissue samples, the positive correlation between IGF2 and miR-483-3p is indicated (R= 0.69, 
p<0.0001);  (B) 22 colorectal cancer samples were related to 5 normal colon mucosa tissues,  the positive 
correlation between IGF2 and miR-483-3p is indicated (R= 0.86, p<0.0001); (C) 19 breast cancer and 4 normal 
breast tissues samples were tested for the expression of miR-483-3p.  
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miR-483-3p protects cells from apoptosis. To start unravelling the molecular basis of the 
potential oncogenic role of miR-483-3p, I focused on the apoptosis pathway because 
important pro-apoptotic human genes are predicted target by miRanda and TargetScan 
algorithms (BBC3/PUMA, AMID, BAX, BIK, SMAC/DIABLO, PDCD1, PDCD7).  Thus, I 
evaluated apoptosis and cell viability in response to modulation of miR-483-3p in HEK293, 
HCT116 and HepG2 cells.  
After treatment of HEK293 cells with doxorubicin to induce apoptotic cell death, transfection 
of miR-483-3p induced a low (10%) but significant increase in cell viability (p-value = 0.05), 
whereas transfection of anti-miR-483-3p AMOs induced a further 15% decrease in cell 
viability (p-value = 0.02) (Fig. 5A). These results indicate that miR-483-3p could promote 
cell survival. 
HepG2 cells express very high level of miR-483-3p. Therefore, I evaluated only the effect of 
anti-miR-483-3p AMO in this cell line. Cell growth was 30 to 40% inhibited by transfection 
of anti-miR-483-3p AMO (Fig. 5B). Simultaneously, cells exhibited a 2.6 fold increase in the 
level of cell death than control cells transfected with a negative control AMO (p-value = 
0.016) (Fig. 5C), as detected by in situ cell death using fluorescent labelling of DNA strand 
breaks with TdT (Terminal deoxynucleotidyl transferase).  
To confirm that the mechanism was indeed apoptosis, caspase 3/7 activity was measured in 
HCT116 cells transfected with miR-483-3p or anti-miR-483-3p and treated with the apoptotic 
inducing factor Nutlin-3A.  Compared to the controls, caspase activity exhibited an 80% 
increase in antimiR treated cells and a 60% decrease in miR-483-3p treated cells (Fig. 5D); 
moreover, I detected an inverse correlation between the amount of transfected miR-483-3p 
and caspase 3/7 activity, whereas a proportional increase was detected between AMO-483-3p 
and caspase 3/7 activity.   
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Figure 5. AMO-483-3p induces cell death. (A) Cell 
viability measured by the MTT assay in HEK293 cells. 
Each value represents the average absorbance ± standard 
deviation from three different experiments. The differences 
between miR-483-3p versus Negative Control 2 (p=0.002), 
and AMO_miR-483-3p versus AMO Negative Control 
(p=0.03) were both statistically significant. (B) Cell 
viability of HepG2 cells at 48 hours following transfection 
of AMO-miR-483-3p or AMO Negative Control. Each 
value represents average ± standard deviation from three 
different experiments (p=0.02 on AMO_miR-483-3p 
versus AMO Negative Control) and related to control data. 
(C) TUNEL staining of HepG2 cells after transfection of 
AMO-Negative Control or AMO miR-483-3p. Cells were 
stained 24 hours after transfection. Underneath the images, 
the average number of fluorescent spots is shown: data in 
each column represent the average ± standard deviation of 
fluorescent spots from three independent fields 
(p=0.0162). (D) Caspase 3/7 activity in HCT116 cells 
transfected with miR-483-3p, anti-miR-483-3p AMO or 
Negative controls; after 24 hours, cells were treated with 
Nutlin-3 (5µM) for additional 6 hours.  
 
 
 
 
 
PUMA is targets of miR-483-3p. In the list of potential pro-apoptotic target genes, 
BBC3/PUMA (BCL2 binding component 3 / p53 upregulated modulator of apoptosis) gene 
was chosen for further analysis because of its known pivotal role in induced cell death 
46
.   
To test the direct interaction of miR-483-3p with 3’UTRs, the predicted wild type and mutant 
miR-483-3p target sites of PUMA mRNA gene was cloned downstream of the luciferase 
reporter gene of pGL3-Control vector. The HEK293 cells were used as biological system 
because they exhibit a low expression of miR-483-3p, HCT116 cells have a medium 
expression whereas the HepG2 cells exhibit a high expression of miR-483-3p (Fig. 6).  
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Figure 6. miR-483-3p relative expression analysis by quantitative real time PCR on 14 cell lines. Each sample 
data was normalized on the RNU6B (∆Ct method) and related to the HEK293 miR-483-3p expression (∆∆Ct 
method).  
Dependently the miR-483-3p expression the miR-483-3p responsive vector was co-
transfected with miR-483-3p into HEK293, either miR-483-3p or antimiR-483-3p 
oligonucleotide (anti-483-3p AMO) into HCT116 cells and only antimiR-483-3p into HepG2 
cells (Fig. 7A). In comparison with control vector, miR-483-3p induced a decrease in 
luciferase activity of about 38% (HEK293) and 45% (HCT116) of the pGL3 vector carrying 
the PUMA-3’UTR, whereas in the mutated 3’UTR clone the luciferase activity was not 
significantly down-regulated by miR-483-3p. Conversely, the use of anti-miR-483-3p AMOs 
induced an increase in luciferase activity of about 70% and 39% for HCT116 and HepG2 
cells, respectively (Fig. 7B).  
To further confirm PUMA as target of miR-483-3p, its protein level was assessed by western 
blot analysis on HEK293 and HepG2 cells transfected with miR-483-3p or antimiR-483-3p 
respectively. Protein expression was reduced (70%) in HEK293 and induced (40%) in HepG2 
cells when compared to the controls (Fig. 7C).   
The analysis of two matched Wilms’ tumors / normal kidney samples for the expression of 
PUMA protein revealed that, as predicted by the molecular function of miR-483-3p, the level 
of expression of these two pro-apoptotic proteins was significantly lower in tumors, where 
miR-483-3p is expressed at higher level (Fig. 7D).  
To further support these data I generated stable cell lines over-expressing the miR-483-3p or 
the antimiR-483-3p to evaluate the expression of BBC3/PUMA after treatment with 5-
Fluorouracil (5FU) as an apoptosis inductor factor that involve the P53 pathway.  The 
HCT116  
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Figure 7. BBC3/PUMA is target 
of miR-483-3p. (A) Putative 
binding site of miR-483-3p in 
PUMA 3’UTRs (miRBase Target 
Database). Asterisks show 
nucleotides substituted in miR-
483-3p predicted target site to 
perform luciferase assay 
(GGAGT>AATTA). (B) PUMA 
3’UTRs regulates luciferase 
activity dependent on miR-483-3p 
in HEK293, HCT116 and HepG2 
cell lines (WT, wild type; MUT, 
mutant; p, p-value). Firefly 
luciferase activity was normalized 
on Renilla luciferase activity of 
the cotransfected pRL-TK vector. 
(C) Western blot analysis of 
PUMA after miR-483-3p 
transfection in HEK293 and 
HepG2 cell line, the  (23 KDa) 
and  (18 KDa) isoforms are 
indicated. Cells were collected 
after 48 hours after miRNA 
transfection. (D) Western blot 
analysis of PUMA in Wilms’ 
tumor samples (T) and matched 
normal tissues (N).  
 
cells were infected with lentiviral vectors over-expressing miR-483-3p (LV-483) or antimiR-
483-3p (LV-AS483), whereas the HepG2 cell line was infected with LV-AS483. An empty 
vector as control was used (LV-CTRL). The increased concentrations of 5FU match with the 
increased PUMA protein levels only in the HCT116 and HepG2 cells over-expressing the 
antimiR-483-3p (Fig. 8A), in spite of a homogeneous increment of BBC3/PUMA mRNA 
levels (Fig. 9A) in all stable cell lines. The induction of both BBC3/PUMA and 
CDKN1A/p21 mRNA levels by 5FU treatment suggest the activation of P53 pathway (Fig. 
9A-B).  
To assess the physiologic role of this finding, the caspase 3/7 activity of these stable cell lines 
was measured after 5FU treatment. Compared to controls the HCT116-LV-483 cells showed 
a reduced caspase 3/7 activity (24- 40%, p<0.0001) (Fig. 8B) whereas the HCT116-LV-
AS483 exhibited an increased activity (4 to 28%, p: 0.03). As expected also in HepG2-LV-
AS483 cells the caspase activity was increased (21 to 70%, p<0.0001) (Fig. 8B).  To further 
prove the connection between miR-483-3p, PUMA and apoptosis, I proved that by knocking 
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down PUMA by siRNA transfection, I could prevent the AS483-3p effect in HepG2-LV-
AS483 cells (Fig. 8C). I used the HepG2 stable cell lines because the efficacy of the anti-
miR-483-3p is more evident than the HCT116 model (Fig.8B). 
 
Figure 8.  Stable cell lines over-expressing antimiR-483-3p are more sensitive to apoptosis stimuli. 
HCT116 cells over-expressing the miR-483-3p (LV-483) or the antimiR-483-3p (LV-AS483) and HepG2 cells 
over-expressing the antimiR-483-3p were treated with different concentration of 5-Fluorouracil. LV-CTRL 
indicates stable cell line with the empty vector. (A) Western blot analysis reveals an increment of PUMA 
protein levels only in the cells LV-AS483. (B) Caspase 3/7 activity was decreased in LV-483 cells and increased 
in LV-AS483 when compared with LV-CTRL cells. Data were normalized on LV-CTRL cells. (C) Relative 
caspase 3/7 activity in HepG2-LV-CTRL and LV-AS483 after treatment with 5FU and siPUMA (+) or siRNA 
scramble (-).Data were normalized on average of caspase activity of HepG2-LV-CTRL cells. 
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Figure 9 CDKN1A/P21 RNA 
induction in stable cell lines 
after 5-Fluorouracil 
treatment. qRT-PCR analysis 
of CDKN1A/P21 expression 
was normalized on 18S RNA.  
 
 
 
 
 
 
 
AMO-miR-483-3p but not IGF2 siRNA can inhibit in vivo tumorigenicity. The potential 
oncogenic role of miR-483-3p was directly tested through tumorigenicity modulation of the 
human HepG2 cells, which over-expresses miR-483-3p. Twenty-four hours after transfection 
of AMO-483-3p or siRNA anti-IGF2 into HepG2 cells, a qRT-PCR confirmed the specific 
reduction of miR-483-3p or IGF2 mRNA, respectively (Fig. 10A). Then, 10×10
6
 cells (cell 
viability greater than 97%) were intra-peritoneally injected into Nod-Scid mice. Mice were 
sacrificed on day 35 and all tumors for each mouse weighed.  AMO-483-3p mouse group 
showed a significant reduction of number and weight of induced tumors compared to controls 
(p-value <0.05). On the contrary, repression of the IGF2 gene did not show any difference 
from controls (p-value >0.5) (Fig. 10B-C). The three groups of data (CTRL, AMO-483-3p, 
siIGF2) are comparable because of the same nature of the molecules used to silence the miR-
483-3p and IGF2 gene (2’-O-methyl RNA oligonucleotide).  
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Figure 10. AMO-483-3p reduces tumors induced by HepG2 cells in vivo. (A) A qRT-PCR analysis to verify 
reduction of miR-483-3p and IGF2 mRNA after transfection of AMO-483-3p or siRNA anti-IGF2 in HepG2 
cells. (B) Tumors of each mouse were weighed: a significant difference (p<0.05) in tumor weights was found 
between AMO-483-3p and AMO Negative control transfected (CTRL) cells, between siRNA IGF2 and AMO-
483-3p (p<0.02) but not between siRNA IGF2 and AMO-CTRL transfected HepG2 cells (p>0.5). (C) 
Appearance of intraperitoneal HepG2 induced tumors in Nod-Scid mice: the white arrows indicate tumor 
formations. 
 
miR-483-3p expression correlates with the mutational status of Wnt/-catenin genes in 
hepatocarcinoma (HCC). The Wnt/-catenin pathway is one of the most important 
pathways dysregulated in hepatocarcinoma (HCC), colorectal cancer (CRC) and Wilms’ 
tumor 
47-49
. Since I previously found that miR-483-3p is up regulated in these cancers as well, 
I investigated the possible involvement of Wnt/-catenin in miR-483-3p dysregulation. Since 
miR-483-3p is located within intron 2 of the IGF2 gene I previously found a positive 
correlation between IGF2 and miR-483-3p expression in HCC (R=0.69, p<0.0001), CRC 
tumor samples from HCC that have a low coefficient of correlation, exhibited a divergent 
expression of IGF2 and 
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Table 2. Mutational status of Wnt/β-catenin genes is associated to miR-483-3p expression.  24 HCC samples 
analyzed for IGF2, miR-483-3p expression and for the mutational status of CTNNB1 exon 3, APC and Axin genes.  
Sample miR-483-3p 
relative 
expression 
IGF2 relative 
expression 
Ratio 483/IGF2 CTNNB1 ex 3 status APC status (NM000038 
from nt 3361 to 4840) 
Axin 1 status 
(NM003502 from nt 745 to 
2186) 
HCC_01 0.02 0.03 0.9 0 0 0 
HCC_02 0.09 1.55 0.1 GAC->TAC_Asp32->Tyr 0 NC 
HCC_03 0.15 0.04 3.8 0 0 0 
HCC_04 0.16 12.47 0.0 0 0 0 
HCC_05 0.21 0.17 1.3 0 NC NC 
HCC_10 1.12 0.14 7.7** 0 0 NC 
 HCC_12 1.32 0.67 2.0 NC 0 NC 
HCC_13 1.44 0.12 11.7** 0 0 0 
HCC_14 2.20 17.90 0.1 0 0 0 
HCC_16 2.92 0.22 13.3* 0 0 NC 
HCC_17 3.47 3.58 1.0 0 0 0 
HCC_18 3.54 3.18 1.1 0 0 0 
HCC_20 4.47 18.02 0.2 NC NC NC 
HCC_21 6.63 0.94 7.0** 0 del 3719-3740 0 
HCC_22 9.55 4.15 2.3 0 0 0 
HCC_23 11.63* 10.89 1.1 TCT->CCT_Ser37->Pro 0 0 
HCC_25 15.73* 3.01 5.2** TCT->TAT_Ser37->Tyr 0 0 
HCC_26 24.98* 0.32 77.1** CAT->CCT_His36->Pro 0 0 
HCC_28 55.52* 17.62 3.2 0 0 0 
HCC_29 66.03* 1.26 52.3** 0 0 del 1024-1027nt 
HCC_30 69.23* 12.29 5.6** GAC->GGC_Asp32->Gly 0 0 
HCC_31 116.16* 11.78 9.9** 0 0 0 
HCC_33 374.10* 1050.30 0.4 0 0 NC 
HCC_34 388.40* 63.37 6.1** 0 NC CCT->ACT_Pro486->Thr 
NC; not classified 
0; not mutated  
* miR-483-3p expression values greater than the considered cut-off (10) 
**miR-483-3p/IGF2 expression ratio values greater than the considered cut-off (5) 
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miR-483-3p suggesting alternative mechanisms regulating these two genes.  I analyzed the 
mutational status of APC, CTNNB1 and Axin1 in 24 HCC samples in which miR-483-3p and 
IGF2 expression had already been assessed 
40
. Mutations in these three genes were previously 
proposed as a major cause of activation of the Wnt/-catenin pathway in cancer 50 51 28. With 
a miR-483-3p expression cut-off level of 10-fold over the average expression of the controls, 
I detected an association between miR-483-3p up regulation and mutational status of these 
genes (p=0.053; Fisher's Exact Test) (Tab. 2), whereas no association between IGF2 
expression and the Wnt/-catenin mutational status was found (expression cut off = 10, p > 
0.5; Fisher's Exact Test). These data suggest that -catenin may be involved in the regulation 
of miR-483-3p separately from IGF2. To prove this point I calculated the ratio between miR-
483-3p and IGF2 expression levels (median value =1.3) to identify samples in which they 
were divergent (Tab. 2). A strong association between the miR-483-3p/IGF2 ratio and the 
mutational status of the Wnt/-catenin genes was observed when the ratio is greater than 5 
(p=0.015; Fisher's Exact Test). Overall these data strongly suggest that expression of miR-
483-3p, but not that of IGF2, is associated with the mutational status of the Wnt/-catenin 
pathway. 
The miR-483 locus is regulated by -catenin. Since -catenin is the principal 
transcriptional mediator of the Wnt/-catenin pathway, I investigated its involvement in the 
regulation of the IGF2/miR-483 locus. I cloned the coding sequence of the -catenin gene 
into the expression vector pIRES-Neo2, and tested its expression (Fig 11A top panel) and 
ability to activate the luciferase reporter vector pGL3-OT containing the -catenin/TCF 
responsive element (Fig.S1) 
52
. pGL3-OF, which carries a mutated -catenin/TCF binding 
site, was used as a negative control. Then I assessed the expression level of miR-483-3p in 
response to -catenin over-expression in HEK 293 cells. A significant increase in miR-483-
3p expression was detected in cells transfected with pIRES-Neo2-catenin vector compared 
to cells transfected with the empty vector pIRES-Neo2 (Fig. 11A). To confirm these results, I 
transiently knocked-down -catenin by using short interfering RNA technology (siRNA) in 
HCT116 cells that exhibits a higher catenin nuclear activity, and miR-483-3p expression, 
compared to HEK293 cells. qRT-PCR verified the decrease of -catenin mRNA after siRNA 
treatment (Fig.S1B), and a significant reduction of miR-483-3p expression was detected only 
in cells transfected with -catenin siRNA (Fig.12B). 
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Figure 11. Induction of miR-
483-3p expression by β-
catenin. (A) miR-483-3p was 
induced by enforced expression 
of CTNNB1 wild type. 
Expression value was related to 
the miRNA expression on 
empty vector transfected cells 
(2
-∆∆Ct
).The expression of 
CTNNB1 was assessed by 
western blot (top panel). (B) 
Expression analyses across the 
IGF2 locus modulated by the 
enforced expression of β-
catenin. Three PCR products 
were designed to amplify IGF2 
exon junctions (Ex_1/2, Ex_2/3, 
Ex_3/4) and one its 3’UTR 
(3’UTR). One set of primers 
was located within intron 2 and 
was used to assess the 
expression of miR-483 
precursor (intron_2). qRT-PCRs 
were carried out with SYBR 
green technologies. RNA was 
previously treated with DNAse 
to avoid genomic 
contamination. Black bars show 
the expression detected in cells 
transfected with the CTNNB1 
expressing vector; white bars 
show the expression detected in cells transfected with the Empty vector. (C) Expression analysis of the miR-
483-3p, miR-483-5p, primiR-483 and IGF2 genes assayed by qRT-PCR using TaqMan probes after LiCl 
treatment (20mM for 24hours) with and without siRNA for CTNNB1 gene. IGF2 expression was still induced, 
although more weakly than the control (Fig 11C). This IGF2 induction by LiCl has not been previously 
described and is not necessarily due to -catenin because of the large number of pathways affected by GSK3B 
inihibition. Single asterisk indicates a p value<0.02. 
 
Next I investigated the effect of -catenin on IGF2 expression. By real time PCR (RT-qPCR) 
I evaluated the expression of different DNA segments across the IGF2 gene locus using 5 
sets of primers spanning the junctions between the IGF2 cDNA sequence and the IGF2 intron 
2. The only DNA segment whose transcription was induced by -catenin was within the 
second intron of the IGF2 that includes miR-483-3p (Fig 11B). Thus I concluded that -
catenin activates a miR-483-3p promoter inside the second intron of IGF2.  
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Figure 12. (A) Ability to activate the luciferase reporter vector pGL3-OT containing the b-catenin/TCF 
responsive element by exogenous expression of b-catenin. pGL3-OF, which carries a mutated b-catenin/TCF 
binding site, was used as a negative control.  (B)  miR-483-3p (white bars) and CTNNB1 (black bars) relative 
expression in HCT116 cell line transfected with CTNNB1 and GAPDH siRNAs at 36 hours from transfection 
 
To further confirm these results, I stabilized -catenin protein by treating HEK293 cells with 
lithium chloride (LiCl), an inhibitor of GSK3 which is responsible for -catenin 
degradation. Figure 11 shows that expression of the entire IGF2/miR-483 locus (miR-483-3p, 
5p, pri-miR-483 and IGF2) was significantly activated (3 to 5 fold) by LiCl treatment. 
Conversely, treatment with -catenin siRNA resulted in reduced expression of the miR-483 
locus after LiCl treatment. IGF2 expression was still induced, although more weakly than the 
control (Fig 11C). This IGF2 induction by LiCl has not been previously described and is not 
necessarily due to -catenin because of the large number of pathways affected by GSK3B 
inihibition. Taken together, these results suggest that the miR-483 locus expression can be 
driven by -catenin independently from IGF2.  
The zinc finger CCCTC-binding factor CTCF represses the genomic region upstream of 
the miR-483 locus. To explore the connection between -catenin and expression of the miR-
483 locus I cloned 4 fragments of different length including the putative miR-483 promoter 
(Fig 13A) upstream of the luciferase gene into the pGL4 enhancer vector (pGL4E). Figure 
13B shows LiCl treatment causes significant induction of luciferase activity for all fragments 
except the small clone pGL4E-6907 (Fig 13B).  
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Figure 13. Analysis of 
the miR-483 minimal 
promoter region 
responsive to 
LiCl/CTNNB1 stimuli.  
(A) Genomic structure of 
IGF2/483 locus from the 
reference AF517226 
genomic sequence. Exons 
(black bars), start 
(ATG_5947) and stop 
codon (TGA_8745), the 
Ebox elements (gray 
triangle), the two 
predicted CTCF binding 
sites (black triangle), 
three CpG dinucletides 
around the CTCF binding 
sites (black circles), miR-
483-3p and miR-483-5p 
(gray boxes) are shown. 
Are indicated the 5 
genomic fragments 
cloned upstream the 
luciferase reporter gene in 
pGL4E for the analysis of 
the promoter on the 
bottom of the panel. The 
genomic region with 
insulator activity studied 
by Du et al. is indicated 
(broken line). (B) Luciferase activity of 4 genomic fragments cloned in pGL4E with and without LiCl treatment, 
the pGL4E empty vector was used as control. (C) Luciferase activity of the pGL4E_6487 wild type (WT) and 
the pGL4E_6487 mutated in the predicted CTCF binding sites (CTCFmut1and CTCFmut2). (D) Analysis of the 
Ebox element wild type (Ebox wt) and mutant (Ebox mut) by luciferase assay on the pGL4E_6487 CTCF mut1 
and pGL4E_Ebox. Firefly luciferase activity was normalized on Renilla luciferase activity of the cotransfected 
pGL4R vector. Single asterisk indicates a p value<0.02, double asterisk indicates a p value>0.02. 
Thus I inferred that the genomic region responsive to LiCl treatment is located between 
positions 6841 and 6907 of the reference sequence AF517226.  
Because the luciferase activity in each of these vectors with or without LiCl treatment was 
always lower than the control (pGL4E empty vector), I suspected the presence of a repressive 
element within this region. Du et al. has shown that a 151 bp fragment (called IGF2-CBI by 
the authors, Fig 13A), immediately upstream of the miR-483 stem loop, has strong insulator 
activity and binds to the CTCF repressor 
53
. CTCF is an important methyl sensitive regulator 
of transcription involved in the epigenetic regulation of genomic imprinted loci such as the 
IGF2/H19 locus in 11p15.5.  
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Table 3. Methylation status of the 3 CpG dinucleotides close to the  CTCF binding site 
Cell line miR-483-3p 
relative 
expression 
Methylation 
status CpG 1 
(%) 
Methylation 
status CpG 2 
(%) 
Methylation 
status CpG 
3 (%) 
H460 0.015 0 50 0 
SNU 423 0.022 0 50 0 
PLC/PRF/5 0.029 0 0 0 
SNU 449 0.042 0 50 50 
MDA MB231 0.23 75 100 50 
K562 0.639 25 50 nc 
SW 480 0.697 0 0 nc 
SNU 387 0.759 25 50 nc 
SKHEP 1 0.789 0 0 0 
HEK293 1 50 100 100 
MCF7 3.543 75 100 100 
HEPG2 23.87 100 100 100 
HUH 7 44.985 100 100 100 
HEPG2-C3A 51.464 75 100 100 
 
 CTCF binds DNA elements called insulators which set limits on the action of enhancer or 
silencer elements permitting to the genome to be organized in functional regulatory domains 
54. It is involved in Wilms’ tumor 16 55 56, breast cancer 57 58 and prostate cancer 59.   I decided 
to determine if CTCF is also involved in the repression of the IGF2/mir-483 genomic regions 
I cloned. Using bioinformatics tools (http://insulatordb.uthsc.edu) I identified two possible 
CTCF binding sites (CTCF BS_1, CTCF BS_2) (Fig 13A). By transfecting the pGL4 vectors 
with mutated versions of either CTCF BS_2 or CTCF BS_1 to prevent CTCF binding, I 
observed a  2 or 4 fold increase of the luciferase activity compared to the wild type control 
(Fig 13C). Since the CTCF repressor only binds demethylated DNA, I analyzed the 
methylation status of 3 CpG dinucleotides close to the CTCF binding sites in a set of 14 cell 
lines. I found a significant positive correlation between the methylation level of the first CpG 
(CG_1, Fig 13A) and miR-483-3p expression (R=0.682, p=0.007), whereas the correlation 
with each of the other 2 CpGs was less significant (Tab 3). These data indicate that CTCF is 
an important regulator of the miR-483 locus and this regulation is likely affected by DNA 
methylation. 
The transcription factor USF1 serves as a mediator between -catenin and the miR-483 
locus. The minimal genomic region responsive to LiCl treatment (between nucleotides 6841 
and 6907) contains an E-box motif (CACGTG) that could bind the basic Helix-Loop-Helix 
(bHLH) protein family. One of these bHLH proteins is the MYC transcription factor, a well 
known target of the Wnt/-catenin pathway, therefore it is reasonable to speculate that MYC 
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could be involved in the LiCl regulation of the miR-483 locus. To test this hypothesis, I 
mutated the pGL4E-6487 in the E-box site and also mutated CTCF BS_1 to partially 
eliminate the repressive activity of this region. After co-transfection of -catenin and the 
reporter vectors into HEK293 cells there was a significant induction of luciferase activity in 
the wild type but not in the E-box mutant clone (Fig 13D). This confirmed the data obtained 
after LiCl treatment (Fig 13B) and identified within the E-box motif the sequence responsive 
to the -catenin/LiCl stimulation. Similar results were obtained with the vector clone 
containing only 69 base pairs around the E-box motif (pGL4E-6841-6910) (Fig 13D). 
 
 
Figure14. MYC transcription factor repress miR-483 transcription. (A) PrimiR-483 expression in HEK293 cells 
transfected with siRNA control (siCTRL) and specific a siRNA for MYC (siMYC), (B) on the same samples the 
MYC and CTNNB1 protein were assessed by western blot to ensure the MYC silencing and that CTNNB1 was 
not involved in this experiment (upper panel). The lower panel shows the MYC mRNA expression by qRT-
PCR. (C) Luciferase activity of the pGL4E_Ebox wild type (wt) with and without treatment with LiCl in 
HEK293 cells transiently knocked down for MYC by siRNA (siMYC). Firefly luciferase activity was 
normalized on Renilla luciferase activity of the cotransfected pGL4R vector. Single asterisk indicates a p 
value<0.02, double asterisk indicates a p value >0.02.  
 
Then I determined whether MYC is the -catenin mediator for miR-483 transcriptional 
activation. Since MYC is well expressed in HEK293 cells I knocked-down its expression 
using a specific siRNA and measured the relative expression of the precursor of miR-483 
(pri-miR-483). Unexpectedly, this resulted in an increase in the expression of pri-miR-483 
(Figs 14A-B). Similar results were obtained by a luciferase assay using the pGL4E-Ebox 
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reporter vector in cells cotransfected with siRNA for MYC. These data indicate that MYC is 
not the responsible for the activation of the miR-483 locus after -catenin activation because 
of its suggested repressive role on miR-483 transcription. 
Figure 15. USF1 
serves a mediator 
between β-catenin 
and the miR-483 
locus. (A) EMSA of 
nuclear extract from 
HEK293 cells using 
the miR-483 Ebox 
probe.  (lane 1-3, 5-
7) or the mutant 
form (lane 4). The 
specific complexes 
are indicated by 
black arrows (b,c,d 
and e). Lane 7 
shows the supershift 
generated by USF1 
antibody (complex 
a). (B) Luciferase 
assay of 
pGL4E_Ebox wild 
type after enforced 
expression of USF1 
and CTNNB1 using 
the pGL4E empty 
vector as control 
(left panel). The 
middle and right 
panels show the 
expression of miR-
483-3p and IGF2 
gene, respectively, 
after enforced expression of USF1 and CTNNB1. The miR-483-3p and IGF2 expression value of the empty 
vector were the controls. The exogenous expression of USF1 was assessed by western blot (upper panel). (C) 
Nuclear extract from HEK293 were immunoprecipitated with either USF1 (lanes 1-3) and CTNNB1 antibodies 
(lanes 4-6). After being washed, samples were run on SDS-PAGE gel and transferred to nitrocellulose. The blots 
were probed with USF1 and CTNNB1 antibody. (D) Nuclear extract from HEK293 with (lanes 1, 2) and 
without (lanes 3, 4) treatment with LiCl (20 mM for 24h) were imunoprecipitated with USF1 antibody and the 
blot probed for CTNNB1 protein. The Input shows an incremented quantity of CTNNB1 after LiCl treatment 
(lanes 5, 6). Vinculin protein expression was used as loading protein control. (E) GST-CTNNB1 and HIS-USF1 
fusion proteins were subjected to GST (lanes 1,2) and HIS (lanes 3-5) pull-down analysis. Binding reaction 
products were washed, and proteins were separated by SDS-PAGE. The membrane was probed with both anti-
CTNNB1, anti-USF1 and and GST antibodies. Single asterisk indicates a p value<0.02, double asterisk indicates 
a p value >0.02. 
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Since the Ebox element can also bind to the Upstream Stimulating Transcription Factor 1 
(USF1) I tested this interaction by Electrophoretic Mobility Shift (EMSA) and Super Shift 
assays, although no previous connection between USF1 and -catenin has been shown. USF1 
is an evolutionary well conserved and ubiquitously expressed transcription factor involved in 
a wide number of cellular activities such as immune response, cell cycle and proliferation, 
and lipid and glucose metabolism 
60
. As shown in Figure 15A the EMSA assay generates a 
specific band shift pattern (complex b to e, lane 2, Fig 15A) that disappears in the mutant 
form of the Ebox element oligonucleotide (lane 4, Fig 15A). Moreover, by using the anti-
USF1 antibody, a super-shift complex was generated (complex a, lane 7, Fig 15A) suggesting 
that USF1 recognizes the Ebox element upstream of the miR-483 locus. 
Figure 16. (A) Western blot 
analysis of catenin and USF1 in 
HEK293 cells transfected with the 
catenin expression vector. 
Vinculin was used as protein load 
control .(B)  Western blot analysis 
of USF1 protein in HepG2 cells 
transfected with USF1 siRNA at 72 
hours from transfection (upper 
panel) and the corresponding miR-
483-3p relative expression (lower 
panel). Single asterisk indicates a p 
value<0.02, double asterisk 
indicates a p value >0.02. 
 
 
 
 
 
To confirm this result I cloned the coding sequence of the USF1 gene into pCMV-Tag vector 
and co-transfected it into HEK293 cells along with pIRES-Neo -catenin and the reporter 
vector pGL4E-6841-6910 with a wild type or mutant E-box (Fig 15B left panel). USF1 over 
expression was able to induce luciferase activity (2 fold) that was further increased in the 
presence of exogenous -catenin (about 3 fold) compared to the control. Similar results 
obtained by RT-qPCR for miR-483-3p showed that miR-483-3p was weakly induced by 
exogenous USF1 (p=0.05) but increased about 3 times with co-expression of USF1 and 
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CTNNB1 (p<0.02) (Fig 15B middle panel). Note that IGF2 expression was unchanged (Fig 
15B right panel). To exclude a transcriptional regulation of USF1 by -catenin, Ialso tested 
that the USF1 protein level after -catenin enforced expression was not changed (Fig.16A). 
These data suggest USF1 is an important mediator of the regulation of miR-483 locus driven 
by the -catenin.  To further confirm these results, Itransiently knocked-down USF1 by 
siRNA in HepG2 cells that show a very high -catenin activity and miR-483-3p expression. 
qRT-PCR verified a significant reduction of miR-483-3p expression, compared to the control, 
after 72 hours from siRNA transfection (Fig.16B). These data suggest USF1 is an important 
mediator of the regulation of miR-483 locus driven by the -catenin.   
-catenin and USF1 directly interact. To understand the interplay between -catenin and 
USF1 I tested the possibility of interaction between these two proteins. I co-
immunoprecipitated from HEK293 nuclear extract lysate with either an anti-USF1 antibody 
or an anti--catenin antibody then immunoblotted with either anti--catenin or anti-USF1, 
respectively and found the two proteins co-immunoprecipitated (Fig 15C). Since LiCl 
treatment is able to induce miR-483 locus expression I tested the ability of -catenin to co-
immunoprecipitate with USF1 with and without LiCl treatment. Western blot analysis 
revealed an increased quantity of -catenin immunoprecipitated with anti-USF1 (22%) 
compared to the non-treated control (Fig 15D) where the induction of -catenin protein level 
after LiCl treatment was increased about 60%. 
Then I tested whether these two proteins have the ability to directly interact by using the 
purified proteins CTNNB1-GST and USF1-HIS in pull-down assays. Both the pull-down 
assays revealed direct interaction between the two proteins (Fig 15E).  
miR-483-3p reveals a negative regulative loop by targeting -catenin. Since regulative 
feed-back loops between microRNAs and their targets have been shown in numerous cases 
61
 
62
 
63
 I investigated the possibility that -catenin and/or USF1 are targets of miR-483-3p or 5p. 
By in-silico analysis (http://targetscan.org/) I found that CTNNB1 is a predicted target of the 
miR-483-3p (Fig 17A).  
To test the direct interaction of miR-483-3p with the CTNNB1 3’UTR, either the predicted 
miR-483-3p target site of the CTNNB1 mRNA, or a mutated target site used as a negative 
control was cloned downstream of the luciferase reporter gene in the pGL3-Control vector. 
These miR-483-3p responsive vectors were co-transfected into HEK293 and HCT116 cells 
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with either an RNA oligonucleotide miR-483-3p mimic or a scrambled sequence. A renilla 
luciferase vector (pGL4R) was used as a reference normalization control. In comparison with 
the control vector, the miR-483-3p caused a decrease in luciferase activity of about 30% and 
50% in HEK293 and HCT116 respectively, whereas in the mutated 3’UTR clones luciferase 
activities were not perturbed by miR-483-3p (Fig 17B).  
Figure 17.  β-catenin is a 
target of miR-483-3p. (A) 
Putative binding site of miR-
483-3p in CTNNB1 3’UTRs 
(TargetScan Database). 
Asterisks show nucleotides 
substituted in 3’UTR miR-
483-3p predicted target site to 
perform luciferase assay. (B) 
CTNNB1 3’UTRs regulates 
luciferase activity dependent 
on miR-483-3p in HEK293 
and HCT116 cell lines (WT, 
wild type; MUT, mutant). (C) 
Western blot analysis of 
CTNNB1 after miR-483-3p 
transfection in HEK293 and 
HCT116 cell line. Cells were 
collected after 48 hours after 
miRNA transfection. (D)  
Luciferase activity of the 
reporter vectors pOT and pOF 
in HCT116 co-transfected 
with miR-483-3p and 
scramble oligo (NC2) with and without LiCl treatment. Single asterisk indicates a p value<0.02, double asterisk 
indicates a p value >0.02. 
 
To further confirm -catenin as target of miR-483-3p, the protein level was assessed by 
western blot of HEK293 and HCT116 cells transfected with miR-483-3p. Protein expression 
was reduced about 20% and 50% when compared to negative control (Fig 17C).  Moreover, 
in HCT116 cells that harbour a mutated -catenin, the co-transfection of miR-483-3p and the 
reporter vector pGL3-OT revealed a functional reduction of nuclear -catenin of 
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approximately 60% compared to the controls, with or without LiCl (Fig 17D). These data 
prove that miR-483-3p can inhibit -catenin transcriptional activity.  
The mutated form of-catenin can evade the miR-483-3p regulative loop. Our findings 
suggest a negative regulatory loop between miR-483-3p and -catenin exists. However both 
genes are over-expressed or have higher activity in tumors, suggesting that -catenin could 
escape miR-483-3p regulation. Since it has been described that a single nucleotide 
polymorphism (SNP) within the 3’UTR of the -catenin mRNA target could affect the 
binding of the miRNA 
64
 
65
 
66
 I analyzed the mutational status of the -catenin 3’UTR in 8 
cell lines (RD, MCF7, RKO, SK-NEP1, G401, A204, U2OS, HEK293) and 30 Wilms’ tumor 
samples. I found 2 SNPs, rs2953 and rs4135387 that I cloned into pGL3-control and tested 
for their susceptibility to miR-483-3p regulation by a luciferase assay. No significant 
differences were found (Fig.18).I also determined that miR-483-3p was not mutated in these 
samples. This result led us to speculate that mutations in the coding sequence of -catenin 
may be affecting this process.  
Figure 18. CTNNB1 3’UTRs regulates luciferase activity dependent on miR-483-3p in HEK293 independently 
of the SNPs rs2953 and rs 4135387 when compare to the 
reference sequence wild type. Firefly luciferase activity was 
normalized on Renilla luciferase activity of the cotransfected 
pRL-TK vector. Single asterisk indicates a p value<0.02, 
double asterisk indicates a p value >0.02. 
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Figure 19 The mutated form of β-catenin evades the miR-483-3p regulative loop. (A) Luciferase activity 
during the time (24, 48, 72 hours) of the reporter vectors pOT and pOF in HEK293 co-transfected with the 4 
different CTNNB1 expression vectors (mutational status of the CDS and 3’UTR miR-483-3p target site of 
CTNNB1: CDS/3’UTR) with (lower panel) and without LiCl treatment (upper panel). As experiment controls 
the CTNNB1 3’UTR wild type and mir-483-3p target mutated were cloned in the expression vector 
pIRESNeo2: Empty/WT (E/WT) and Empty/MUT (E/MUT). The p-values are indicated and graphically 
represented in B.  
 
I cloned either the wt -catenin 3’UTR or the 3’ UTR with a mutated miR-483-3p target site 
into two different pIRES-Neo2 -catenin expression vectors, one with wt -catenin  and the 
other with a Ser45 deletion. As a control vector with only the 3’UTR and no coding sequence 
was used. The 6 combinations of vectors were transfected into HEK293 cells and -catenin 
nuclear activity was measured by the pGL3-OT (list the pGL3-OF in figure legend) luciferase 
reporter vector after 24, 48 and 72 hours. This allowed evaluation of the 2 different types of 
negative regulation of -catenin (GSK3B mediated degradation and miR-483-3p mediated 
translational inhibition). After transfection in HEK293 cells all forms of -catenin were able 
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to increase the luciferase activity of the pGL3-OT at 24, 48 and 72 hours compared to the 
controls (Fig 19A) however I did not seen any significant difference between the WT/WT 
and WT/MUT forms (CDS/3’UTR). This could be due to the high rate of GSK3B-mediated 
-catenin degradation which is strong in HEK293 cells and could hide the effect of miR-483-
3p. To overcome this problem the experiment was conducted in the presence of LiCl which 
resulted in a significant increase of activity in the presence of the WT/MUT but not the 
WT/WT form suggesting that the wt 3’ UTR is controlled by miR-483-3p, but the mutant 
form is not (Fig 19A and Fig 19B, left panel).  On the other hand the Ser45 mutant form of -
catenin showed a significant difference in regulation by miR-483-3p at the 3’UTR (MUT/WT 
vs MUT/MUT) only at 24 hours without LiCl (p=0.036). Since the mutant form is not 
degraded and thus accumulates in the cells, it is reasonable that at an early time point -
catenin protein levels are still controlled by miR-483-3p but this regulation is lost over time 
(Fig 19B, right panel). Taken together these data support that the activating mutation of -
catenin results in loss of regulation by miR-483-3p. 
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Discussion 
I established a link between miR-483-3p, a miRNA located within the IGF2 locus at 
chromosome 11p15.5, and human tumorigenesis. Various evidences support this conclusion. 
First, tumorigenicity of HepG2, a cell line that over-expresses miR-483-3p, is suppressed by 
AMO anti-miR-483-3p; second, the miRNA is up-regulated and over-expressed in Wilms’ 
tumors, as well as in common human neoplasms; third, miR-483-3p supports cell survival by 
protecting cells from apoptosis; fourth, an important regulator of apoptosis, Puma, is 
inhibited by the expression of miR-483-3p. 
To demonstrate the oncogenic properties of miR-483-3p, I proved that silencing of miR-483-
3p by AMO could reduce tumorigenicity of HepG2 cells, a cell line that exhibits high 
expression of the IGF2/miR-483 locus and functional activity of IGF2 ligand 
67
 
68
. 
Importantly, the reduction in tumor formation by the specific silencing of miR-483-3p was 
achieved without changing IGF2 gene expression. Moreover, the silencing of the IGF2 gene 
by siRNA technologies did not cause a significative changing in tumors formation by HepG2 
cells.  These results clearly indicate that a crucial oncogenic function associated with the 
miR-483-3p miRNA within the IGF2 locus. This conclusion may explain why transgenic 
animal models for Igf2 over-expression did not develop tumors 
21
. In fact, these animal 
models were developed by using an Igf2 cDNA, which lacked the mir-483 locus. It could be 
speculated that, by protecting cells from apoptosis, miR-483-3p provides the additional 
element required for supporting malignant transformation promoted by the growth factor 
IGF2.  Indeed, in Wilms’ tumor, HCC and CRC studied the expression of the IGF2/miR-483 
locus is co-regulated in almost all the samples analyzed. Interestingly, some cases present a 
divergent expressions of miR-483-3p and IGF2, suggesting a possible IGF2 independent 
mechanisms of miR-483-3p regulation. 
By proving that ectopic expression of miR-483-3p can protect cells from apoptosis, while 
inhibition of endogenous miR-483-3p increases basal or induced apoptosis, I demonstrate that 
the up-regulation of miR-483-3p can protect cells from apoptosis. This is in line with the 
finding that miR-483-3p can target and repress the expression of the pro-apoptotic protein 
PUMA, a BH3-only protein, whose induction is mediated by p53 
46,69
. Like other BH3-only 
proteins, it promotes apoptosis by interacting and inhibiting the anti-apoptotic factors BCL2 
and BCLXL 
69-71
. Hence, an over-expressed miR-483-3p may favor cell survival by reducing 
the level of Puma after P53 activation during apoptosis stimuli, and therefore acting as an 
anti-apoptotic oncogene. These results support this conclusion. 
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The involvement of miR-483-3p in cancer is supported by the observation that is over-
expressed in about 30% of common human cancers and in 100% of Wilms’ tumors. In 
addition, Guled et al. reported the up-regulation of miR-483-3p in malignant mesothelioma 
41
.  
In human cancers the over-expression of miR-483-3p could be linked to its co-regulation with 
IGF2 expression. Interestingly, through this mechanism, both growth, IGF2, and survival 
stimuli, miR-483-3p, are simultaneously activated.  
However some tumor samples displayed a divergent expression between IGF2 and miR-483-
3p, thus revealing the existence of mechanisms where IGF2 and hsa-mir-483 are not co-
regulated. Therefore I investigated also this aspect of the research. I identified a new 
molecular mechanism of auto-regulation of -catenin activity through miR-483-3p, and a 
novel interaction between the transcription factors USF1 and -catenin. After genetic analysis 
of HCC samples, I identified an association between the activation of the -catenin pathway 
and the over-expression of miR-483-3p, an association that was stronger in a subset of 
samples that exhibited a divergent expression between IGF2 and miR-483-3p. This 
observation was supported by the finding that the miR-483 locus could be up-regulated 
independently from its host gene IGF2 by enforced over-expression of -catenin.  
These findings indicate the existence of at least two mechanisms responsible for the 
expression of miR-483-3p: co-regulation with IGF2 and transcriptional induction by β-
catenin. The first mechanism appears to be significantly represented in Wilms’ tumors and 
possibly other pediatric tumors. In these tumors, the well-known over-expression and loss of 
imprinting of IGF2 may be responsible for most of the miR-483 up-regulation. Through this 
mechanism, both cell growth and survival can be simultaneously stimulated by IGF2 and 
miR-483-3p, respectively. The second mechanism may explain the over-expression of miR-
483-3p in adult human cancers, where its up-regulation may occur independently from IGF2 
expression.   
The mediator of miR-483 stimulation by -catenin was identified as the basic Helix-Loop-
Helix Upstream Stimulating factor USF1. Here, I prove that it can directly interact with -
catenin and recognize the E-box CACGTG element located 400 nucleotides upstream of the 
miR-483 locus. The interaction between -catenin and another bHLH protein, MyoD, was 
previously described 
72
, but this is the first demonstration of the direct interaction between -
catenin and USF1. USF1 is a widely expressed transcription factor that plays a crucial role in 
the regulation of cell cycle and proliferation 
73,74
 and gluco-lipidic metabolism. 
75,76
.  
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Moreover has been shown USF1 plays also an important role for the maintenance of a 
chromatin barrier at the insulator elements of the chicken -globin gene 77.  
The recent demonstration of the safe and effective use of anti-miRNAs in animal models, 
including African green monkeys, suggest the potential application of AMOs also in anti-
cancer therapy 
78,79
. Our findings indicate the miR-483-3p as a potential target for anti-
neoplastic intervention in Wilms’ and possibly many other tumors.  Thus, these results not 
only improve our understanding on the molecular mechanisms involved in tumor 
development, but they also provide indication for a novel potential therapeutic target.  
My discovery of a negative regulative loop between miR-483-3p and -catenin generates an 
apparent paradox. To explain this discrepancy, I found that the mutated form of -catenin is 
able to evade miR-483-3p regulation and the mutated protein can still accumulate in the cell. 
In addition to the -catenin-USF1 / miR-483 mechanism, in this study I found that CTCF can 
also participate in the regulation of miR-483 expression. Indeed, I confirmed data published 
by Du et al. 
53
, who found that the region immediately upstream of the miR-483 locus binds 
the multifunctional protein CTCF. I found evidence that CTCF could play an important role 
in the regulation of miR-483 locus as a transcriptional repressor and that repression is 
indirectly correlated to the methylation status of a CpG dinucletide in the CTCF binding site. 
CTCF is a well known regulator of imprinted regions of the genome such as the IGF2/H19 
locus where it permits the monoallelic expression of these two genes 
80,81
 by modulating the 
conformation of this region, which 
82
 affects transcriptional activity. It is also important to 
note that the chromosomal region where CTCF is located (16q21) is often deleted in Wilms’ 
tumor 
83,84
. Our finding highlights the role of the miR-483 locus as point of junction among 
the most important players in Wilms’ tumor (IGF2 locus, Wnt/-catenin pathway and 
CTCF). 
By unraveling the complex regulation of the miR-483 locus, the present study provides new 
insight into the Wnt/-catenin pathway and indicates new targets for anticancer therapy.  
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Conclusion and future perspectives 
Hsa-miR-483 is located within intron 2 of the IGF2 locus. IGF2 is a fetal growth factor 
whose abnormally high expression has been associated with the development of 
nephroblastoma, hepatoblastoma and rhabdomyosarcoma. I found that miR-483-3p is 
overexpressed in all the Wilms’ tumors I studied. In addition, colon, breast, and liver cancers 
exhibit high or even extremely levels of miR-483-3p in ~30% of the cases. Functionally I 
found that the miR-483-3p acts as an oncomiR by targeting the pro-apoptotic gene p53 up-
regulated modulator of apoptosis (BBC3/PUMA) 
40,85
.  
The significance of these finding is related to the genomic position of this miRNA that maps 
at the second intron of IGF2 gene on the 11p15.5 chromosomal region called WT2 region 
(Wilms’ tumor region 2) and/or MTACR1 (Multiple Tumor-Associated Chromosomes 
Region1) because of its involvement in several tumors. IGF2 gene has been studied for many 
years in connection to Wilms’ tumor 86 and Beckwith-Wiedemann syndrome (BWS) and it 
was found upregulated. Nevertheless IGF2 murine transgenic models have highlighted 
features close to the Beckwith-Wiedemann syndrome 
21
 without tumor predisposition. 
Recently Hu et al. published a Wilms’ tumor mouse model caused by somatic ablation of 
Wt1 and constitutional up-regulation of Igf2 locus 
87
. Taken together these results suggest an 
important cooperation between IGF2 and miR-483, their co-presence stimulate both cell 
growth and survival in cancer cells.    
Generally a co-regulation of IGF2 and miR-483 was registered even though I identified a 
second regulatory mechanism of miR-483 independently of IGF2 expression. MiR-483 locus 
could be regulated by a novel transcription complex that involves the onco-protein β-catenin 
and the upstream transcription factor 1 (USF1). The β-catenin\Wnt pathway is one of the 
most important pathway dysregulated in cancer and USF1 is an evolutionary well conserved 
and ubiquitous transcription factor (TF) involved in a wide number of cellular activities such 
as cell cycle and proliferation, and lipid and glucose metabolism 
60
.  
I identify the TF CMYC as repressor of the miR-483 locus. This finding could explain the 
pro-apoptotic character of this oncogene 
88,89
and the interesting result obtained by  Okuyama 
et al. They show that c-MYC protein levels cancer cells in vivo are strikingly reduced in the 
area distant from the blood vessels enhancing cell survival 
90
. 
Description of preliminary data 
1. MYC transcription factor represses miR-483 expression. I recently published an auto-
regulative loop between miR-483 and β-catenin transcription factor by the novel interaction 
β-catenin/USF1. During this study I found that CMYC repress the transcription of miR-483. 
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HEK293 cells knocked down for CMYC by short interfering RNA show an incremented 
expression of the pri-miR-483 (Fig.14A-B). These data suggest that CMYC is involved at the 
transcription step of the locus and not during the maturation of the miRs considered. 
Luciferase assay to evaluate the promoter region of the miR-483 locus highlight that the 
CMYC repression is independent from the USF1 binding site (same recognition sequence of 
CMYC) (Fig.14C). 
By Chromatin immunoprecipitation analysis I found that CMYC bounds the miR-483 
promoter (Fig.20B). Has been published that the CMYC repressive function is exerted by the 
mediator myc-interacting zinc finger protein 1 (MIZ-1) 
91
, since I found 4 MIZ-1’s predicted 
binding in the 500 bp up-stream the miR-483 locus (Fig.20A) I suppose an involvement of 
this protein in the regulation of miR-483. 
 
 
Fig.20 (A) Genomic structure of IGF2/483 locus from the reference AF517226 genomic sequence. IGF2’s 
Exons (gray bars), the four predicted MIZ1 binding sites (black bars), miR-483-3p and miR-483-5p (dark gray 
boxes) are shown. Are indicated the 2 genomic fragments amplified for the ChIP analysis. (B) ChIP analysis 
using CMYC and NMYC antibibodies in HepG2 and HCT116 cell lines (B indicates the blank of the PCR). 
 
2. Glucose influences miR-483-3p expression. Since I found USF1 regulates miR-483 
expression 
85
 and that USF1 is regulated by glucose 
92,93
 I evaluated miR-483-3p expression 
in HepG2 cells deprived of glucose. As shown in figure 21 the expression of miR-483-3p is 
gradually down-regulated during the time in cells deprived of glucose. On the other hand in 
presence of glucose the expression of miR-483-3p seems increased over time. The down-
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regulation of miR-483-3p coincides with a down-regulation in the protein level of β-catenin 
but USF1 seems not influenced (data not shown). 
Fig. 21 Time course of miR-483-3p relative expression on HepG2cells 
cultured with and without glucose (0mM and 10mM). The miR-483-3p 
expression was normalized to the endogenous reference RNU6B 
 
 
 
 
 
 
 
 
 
I support the hypothesis that the glucose metabolism could be an important factor in the 
regulation of the anti-apoptotic miR-483-3p, given the 1) location of miR-483 in the INS-
IGF2 gene in the 11p15.5 chromosome region, 2) the involvement of USF1 that seems to be 
necessary to the glucose response 
92
, 3) the β-catenin/Wnt pathway that is regulated by the 
glycogen synthase kinase 3 beta (GSK3B), 4) the inhibition of glucose metabolism is 
described to be an apoptotic stimulus 
94,95
 and 4) our preliminary data that show a down-
regulation of miR-483 in HepG2 cells cultured in absence of glucose. 
 
My future aim is to draw the complex scenario of the regulation of miR-483 locus to identify 
new possible approaches in the treatment of cancers that exhibit miR-483 up-regulation. Our 
preliminary data suggest the involvement of glucose metabolism in the miR-483 regulation, 
moreover I published the involvement of the transcriptional factors USF1 and CMYC in the 
miR-483 regulation that are described implicated in glucose metabolism 
96
 
97
. Since the anti-
apoptotic role of miR-483-3p I suppose that inhibiting the pathway glucose metabolism I 
could improve the drug susceptibility of tumorigenic cells with elevated miR-483 expression. 
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